Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Int J Cancer. 2013 Nov 15;133(10):2325-33. doi: 10.1002/ijc.28251. Epub 2013 May 29.
Inflammatory responses play a vital role at different stages of colorectal carcinogenesis. C-type lectins mediate inflammatory/immune responses and participate in immune escape of pathogens and tumors. Our study aimed to evaluate the correlation between polymorphisms in three C-type lectin genes, CD209, MBL2 and REG4, and colorectal cancer (CRC) risk and clinical outcome. We genotyped 15 potentially functional single nucleotide polymorphisms (SNPs) and assessed their associations with CRC risk in a case-control study of 1353 CRC cases and 767 healthy controls from the Czech Republic. We also analyzed these SNPs in relation to overall and event-free survival in 414 patients. Two CD209 SNPs were associated with CRC risk after adjustment for multiple comparison. Minor allele carriers of the promoter SNP rs2287886 had an increased risk of CRC (OR 1.30, 95% CI 1.08-1.56), while minor allele carriers of the 3'UTR SNP, rs7248637, had a decreased risk (OR 0.74, 95% CI 0.60-0.91). Multivariate survival analyses, including age, gender, TNM stage and grade, showed that patients without distant metastasis at the time of diagnosis and carrying the rs2994809 T allele had a decreased overall and event-free survival (HR 2.11, 95% CI 1.20-3.72 and HR 2.00, 95% CI 1.18-3.39, respectively). We show that SNPs in CD209 may affect CRC risk, while a SNP in REG4 may be a useful marker for CRC progression.
炎症反应在结直肠癌的发生发展的不同阶段发挥着重要作用。C 型凝集素介导炎症/免疫反应,并参与病原体和肿瘤的免疫逃逸。我们的研究旨在评估三种 C 型凝集素基因(CD209、MBL2 和 REG4)的多态性与结直肠癌(CRC)风险和临床结局之间的相关性。我们对来自捷克共和国的 1353 例 CRC 病例和 767 例健康对照者进行了 15 个潜在功能单核苷酸多态性(SNP)的基因分型,并评估了它们与 CRC 风险的关系。我们还在 414 例患者中分析了这些 SNP 与总生存和无事件生存的关系。经过多重比较调整后,两个 CD209 SNP 与 CRC 风险相关。启动子 SNP rs2287886 的次要等位基因携带者 CRC 风险增加(OR 1.30,95%CI 1.08-1.56),而 3'UTR SNP rs7248637 的次要等位基因携带者 CRC 风险降低(OR 0.74,95%CI 0.60-0.91)。包括年龄、性别、TNM 分期和分级在内的多变量生存分析显示,诊断时无远处转移且携带 rs2994809 T 等位基因的患者总生存和无事件生存降低(HR 2.11,95%CI 1.20-3.72 和 HR 2.00,95%CI 1.18-3.39)。我们表明,CD209 中的 SNP 可能影响 CRC 风险,而 REG4 中的 SNP 可能是 CRC 进展的有用标志物。